Learn About Chronic Inflammatory Demyelinating Polyneuropathy

What is the definition of Chronic Inflammatory Demyelinating Polyneuropathy?

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a disorder that involves nerve swelling and irritation (inflammation) that leads to a loss of strength or sensation.

What are the alternative names for Chronic Inflammatory Demyelinating Polyneuropathy?

Chronic inflammatory demyelinating polyradiculoneuropathy; Polyneuropathy - chronic inflammatory; CIDP; Chronic inflammatory polyneuropathy; Guillain-Barré - CIDP

What are the causes of Chronic Inflammatory Demyelinating Polyneuropathy?

CIDP is one cause of damage to nerves outside the brain or spinal cord (peripheral neuropathy). Polyneuropathy means several nerves are involved. CIDP often affects both sides of the body.

CIDP is caused by an abnormal immune response. CIDP occurs when the immune system attacks the myelin cover of the nerves. For this reason, CIDP is thought to be an autoimmune disease.

Health care providers also consider CIDP as the chronic form of Guillain-Barré syndrome.

The specific triggers of CIDP vary. In many cases, the cause cannot be identified.

CIDP may occur with other conditions, such as:

  • Chronic hepatitis
  • Diabetes
  • Infection with the bacterium Campylobacter jejuni
  • HIV/AIDS
  • Immune system disorders due to cancer
  • Inflammatory bowel disease
  • Systemic lupus erythematosus
  • Cancer of the lymph system
  • Overactive thyroid
  • Side effects of medicines to treat cancer or HIV
What are the symptoms of Chronic Inflammatory Demyelinating Polyneuropathy?

Symptoms include any of the following:

  • Problems walking due to weakness or lack of feeling in the feet
  • Trouble using the arms and hands or legs and feet due to weakness
  • Sensation changes, such as numbness or decreased sensation, pain, burning, tingling, or other abnormal sensations (usually affects the feet first, then the arms and hands)

Other symptoms that can occur with CIDP include:

  • Abnormal or uncoordinated movement
  • Problems breathing
  • Fatigue
  • Hoarseness or changing voice or slurred speech
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Chronic Inflammatory Demyelinating Polyneuropathy?

The goal of treatment is to reverse the attack on the nerves. In some cases, nerves can heal and their function can be restored. In other cases, nerves are badly damaged and cannot heal, so treatment is aimed at preventing the disease from getting worse.

Which treatment is given depends on how severe the symptoms are, among other things. The most aggressive treatment is only given if you have difficulty walking, breathing, or if symptoms don't allow you to care for yourself or work.

Treatments may include:

  • Corticosteroids to help reduce inflammation and relieve symptoms
  • Other medicines that suppress the immune system (for some severe cases)
  • Plasmapheresis or plasma exchange to remove antibodies from the blood
  • Intravenous immune globulin (IVIg), which involves injecting antibodies into the bloodstream to reduce the effect of the antibodies that are causing the problem
Who are the top Chronic Inflammatory Demyelinating Polyneuropathy Local Doctors?
Elite in Chronic Inflammatory Demyelinating Polyneuropathy
Elite in Chronic Inflammatory Demyelinating Polyneuropathy

New Jersey Pediatric Neuroscience Institute

385 Prospect Avenue 2nd Floor, 
Hackensack, NJ 
Languages Spoken:
English, Arabic, French
Accepting New Patients

Nizar Souayah is a Neurologist in Hackensack, New Jersey. Dr. Souayah is rated as an Elite provider by MediFind in the treatment of Chronic Inflammatory Demyelinating Polyneuropathy. His top areas of expertise are Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Myasthenia Gravis, and Chronic Polyradiculoneuritis. Dr. Souayah is currently accepting new patients.

Marinos C. Dalakas
Elite in Chronic Inflammatory Demyelinating Polyneuropathy
Neurology | Neuromusculoskeletal Medicine
Elite in Chronic Inflammatory Demyelinating Polyneuropathy
Neurology | Neuromusculoskeletal Medicine

Phoenix Rehabilitation And Health Services Inc

2000 Westinghouse Dr, Suite 200, 
Cranberry Township, PA 
Languages Spoken:
English
Offers Telehealth

Marinos Dalakas is a Neurologist and a Neuromusculoskeletal Medicine provider in Cranberry Township, Pennsylvania. Dr. Dalakas is rated as an Elite provider by MediFind in the treatment of Chronic Inflammatory Demyelinating Polyneuropathy. His top areas of expertise are Stiff Person Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, Hereditary Hyperekplexia, Chronic Polyradiculoneuritis, and Laminectomy.

 
 
 
 
Learn about our expert tiers
Learn More
David P. Randall
Distinguished in Chronic Inflammatory Demyelinating Polyneuropathy
Distinguished in Chronic Inflammatory Demyelinating Polyneuropathy

Advocate Medical Group Neurology

1875 Dempster St, Ste 625/660, 
Park Ridge, IL 
Languages Spoken:
English

David Randall is a Neurologist in Park Ridge, Illinois. Dr. Randall is rated as a Distinguished provider by MediFind in the treatment of Chronic Inflammatory Demyelinating Polyneuropathy. His top areas of expertise are Lambert-Eaton Syndrome, Peripheral Neuropathy, Chronic Inflammatory Demyelinating Polyneuropathy, and Myasthenia Gravis.

What is the outlook (prognosis) for Chronic Inflammatory Demyelinating Polyneuropathy?

The outcome varies. The disorder may continue long term, or you may have repeated episodes of symptoms. Complete recovery is possible, but permanent loss of nerve function is not uncommon.

What are the possible complications of Chronic Inflammatory Demyelinating Polyneuropathy?

Complications of CIDP include:

  • Pain
  • Permanent decrease or loss of sensation in areas of the body
  • Permanent weakness or paralysis in areas of the body
  • Repeated or unnoticed injury to an area of the body
  • Side effects of medicines used to treat the disorder
When should I contact a medical professional for Chronic Inflammatory Demyelinating Polyneuropathy?

Contact your provider if you have a loss of movement or sensation in any area of the body, especially if your symptoms get worse.

What are the latest Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials?
Long-term Extension Study to Evaluate the Safety and Efficacy of Riliprubart (SAR445088) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Summary: This study is a Phase 3 extension, global, multicenter open-label study. The purpose of this study is to evaluate long-term safety and efficacy of riliprubart in adult participants with chronic inflammatory demyelinating polyneuropathy (CIDP) who have completed Part B in 1 of 3 parent studies (PDY16744, EFC17236, or EFC18156) and wish to continue treatment with riliprubart. Up to approximately 300...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Summary: The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.

Who are the sources who wrote this article ?

Published Date: June 13, 2024
Published By: Joseph V. Campellone, MD, Department of Neurology, Cooper Medical School at Rowan University, Camden, NJ. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

What are the references for this article ?

Katirji B. Disorders of peripheral nerves. In: Jankovic J, Mazziotta JC, Pomeroy SL, Newman NJ, eds. Bradley and Daroff's Neurology in Clinical Practice. 8th ed. Philadelphia, PA: Elsevier; 2022:chap 106.

Smith AG, Shy ME. Peripheral neuropathies. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 388.